Virus-Like Particles (VLP’s) Market Analysis And Forecast To 2032: By Product Type (Hepatitis, Cancer/HPV, Gaucher Disease), Source (Yeast, Insect Cell, Plant, Others), Application (Vaccine, Therapeutics), And Region

The global Virus-Like Particles (VLP’s) Market was valued at USD 4.6 Billion in 2022 and it is anticipated to grow up to USD 8.9 Billion by 2032, at a CAGR of 6.8% during the forecast period.

Virus-like particles (VLPs) are multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccine candidates.

Market Trends and Drivers

Consistent R&D activities prominently drive the growth of the overall market. VLPs have gained attention from many researchers, particularly virologists and immunologists. VLP-based vaccines are more immunogenic and safer than traditional vaccines as they cannot replicate, recombine, or undergo reassortment due to the lack of infectious DNA or RNA material.

Market Restraints and Challenges

The feasibility of VLPs as antigen carriers is questionable and complicated due to associated difficulties which is resulting in the sluggish growth of the global market. Therefore, Frontiers S.A. report states that for mutation of the viruses coupled with its adjuvant effect and inflammatory response has to be evaluated by the researchers for development of each new VLP vaccine.

The report analyses the global Virus-Like Particles (VLP’s) Market based on product type, source, application, and region.
Global Virus-Like Particles (VLP’s) Market by Product Type
Based on product type, the virus-like particles market is segmented as hepatitis, cancer/HPV, and Gaucher disease. The hepatitis segment would account for a large market share during 2021-2028. For instance, as per the data published by the Hepatitis B Foundations in 2021, about two billion people are infected with the hepatitis B virus worldwide. To counter such situation utilization of commercialized VLPs vaccines proved effective for hepatitis treatment. Examples of commercialized VLP vaccines are "Recombivax" and "Engerix". These two are the recently commercialized VLP-based vaccines for hepatitis B, and "Gardasil" and "Cervarix" and both are the licensed VLP-based vaccine for human papillomavirus. Today, VLP based vaccines against hepatitis C virus, Ebola, Lassa virus, hantavirus, Marburg, SARS coronavirus, and Chikungunya virus, among others, are in various stages of developmen.
Global Virus-Like Particles (VLP’s) Market by Source
By source, the virus-like particles market is segmented into yeast, insect cell, plant, and others. Based on the source, the yeast segment will record dominating share for the overall market in the coming years. Yeast cells are frequently used for recombinant proteins expression and have been widely used for VLP vaccine production. This is mainly due to advantages such as rapid cell growth, high protein expression yield, easy scalability, cost-effective production, and high degree of post-translational modification (PTM) processes. The Food and Drug Administration (FDA) has approved two VLP-based vaccines - Engerix-B (HBV vaccine) and Gardasil (HPV vaccine) - produced using yeast expression systems.
Global Virus-Like Particles (VLP’s) Market by Application
By application, the virus-like particles market is segmented as vaccines and therapeutics. The vaccines segment would hold a considerable share of the market in 2021, and it is likely to continue its dominance in the market during the forecast period as well. VLP-based vaccines have been developed as an alternative to traditional vaccines owing to their safety, flexibility, and distinctive immunogenic properties. The transmission of infectious or deadly viruses such as HCV poses a serious threat to populations worldwide. The introduction of an HCV vaccine has been projected using simulation models in a high-risk population with posing a significant effect on reducing the incidence of HCV. For example, to avoid such situation, simulation model has been developed by the government focusing on vaccination program aiming to reduce incidences of HCV. Simulation models has proven track record of reducing hepatitis C prevalence through VLP vaccine. With even modest efficacy and coverage VLP vaccine significantly reduces the incidence of hepatitis C among the population as the vaccine has effectiveness up to 50-80% efficacy, targeted to high-risk intravenous drug users, could dramatically reduce HCV incidence among the population. Therefore, VLPs based vaccine represents a safe and highly immunogenic vaccine delivery platform that is able to induce a potent adaptive immune response.

Geographical Analysis of Global Virus-Like Particles (VLP’s) Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Europe is projected to maintain its position as the second-largest market globally during the forecast period. Europe is anticipated to record the highest CAGR, which is attributed to enhanced healthcare infrastructure, facilitated diagnostics, and the growing affordability of diagnostic tests for viral diseases. APEJ and Africa are expected to witness the most promising growth opportunities during the forecast period. China is leading the APEJ market. India holds a considerable revenue share of the APEJ virology market.

Major Players in the Global Virus-Like Particles (VLP’s) Market

The key players in the Virus-Like Particles (VLP’s) Market  Merck & Co., Inc., GlaxoSmithKline plc., Pfizer Inc., Dynavax Technologies, Sanofi, Wantai BioPharm, Serum Institute of India Pvt. Ltd., BHARAT BIOTECH, LG Chem, and VBI Vaccines Inc.. among others.

COVID-19 Impact:

The COVID-19 pandemic has had a profound impact on the hepatitis B virus (HBV) vaccine market. One of the main impacts of COVID-19 on HBV vaccines has been a disruption in the production and supply chain for vaccines. The pandemic has caused disruptions in the supply of raw materials and other inputs needed for vaccine production, as well as in the transportation and distribution of vaccines. This has led to shortages of HBV vaccines and other vaccines in some areas. In addition, the focus on responding to the COVID-19 pandemic has led to delays or reductions in funding for other vaccination programs, including HBV vaccination programs. This may have had an impact on vaccination rates for HBV and other diseases.

Despite the short-term challenges posed by the pandemic, the post COVID outlook for the hepatitis B virus (HBV) vaccine market looks positive. The COVAX Facility, which is led by the World Health Organization (WHO) and aims to provide equitable access to COVID-19 vaccines, has also been working to ensure access to other essential vaccines, including the hepatitis B vaccine. The COVAX Facility has secured more than 2 billion doses of the hepatitis B vaccine and has delivered them to countries around the world. These efforts would drive the production of HBV vaccines during the post COVID period.

Recent Developments:

• In October 2022, Researchers at IIT Delhi in collaboration with the Translational Health Science and Technology Institute (THSTI), Faridabad, Haryana have developed SARS-CoV-2 Virus-Like Particles (VLPs), which are a possible vaccine candidate.
• In October 2019, Icosavax, Inc. today announced the launch of the company with a $51 million Series A financing, led by Qiming Venture Partners USA and joined by Adams Street Partners, Sanofi Ventures and NanoDimension, with continuing support from its seed investors.

Frequently Asked Questions

Q1. How big is the Virus-Like Particles (VLP’s) Market?Ans. The global Virus-Like Particles (VLP’s) Market was valued at USD 4.6 Billion in 2022 and it is anticipated to grow up to USD 8.9 Billion by 2032, at a CAGR of 6.8% during the forecast period.Q2. What is the Virus-Like Particles (VLP’s) Market growth rate?Ans. The growth rate of the Virus-Like Particles (VLP’s) market is 23.1%Q3. Which region holds a major market share for the market?Ans. North America holds a major market share of the Virus-Like Particles (VLP’s) Market in 2022.Q4. Which segment accounted for the largest Virus-Like Particles (VLP’s) Market share?Ans. By application, the vaccine segment accounted for the largest Virus-Like Particles (VLP’s) Market share.Q5. Who are the key players in the kidney stones management market?Ans. The global Virus-Like Particles (VLP’s) Market report includes players are Merck & Co., Inc., GlaxoSmithKline plc., Pfizer Inc., Dynavax Technologies, Sanofi, Wantai BioPharm, Serum Institute of India Pvt. Ltd., BHARAT BIOTECH, LG Chem, and VBI Vaccines Inc.. among others.Q6. What are the factors driving the Virus-Like Particles (VLP’s) Market growth?Ans. The major factors driving the growth of the market are Consistent R&D activities.Q7. What are the key growth strategies of Virus-Like Particles (VLP’s) Market players?Ans. The key growth strategies of Virus-Like Particles (VLP’s) Market players are product launch and product approval.Q8. Which region will provide more business opportunities for the Virus-Like Particles (VLP’s) Market during the forecast period?Ans. The Asia-Pacific region will provide more business opportunities for the Virus-Like Particles (VLP’s) Market during the forecast period.


Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.